Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

Author:

Detoc Maëlle,Bruel Sébastien,Frappe Paul,Botelho-Nevers Elisabeth,Gagneux-Brunon Amandine

Abstract

AbstractBackgroundThe world is facing the COVID-19 pandemic. Development of vaccine is challenging.AimTo determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial.MethodsWe conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial.ResultsThree thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4 % of the responders, 670 (20.6 %) were under 30 years of age, 1,502 (46.1 %) between 30-49 years, 803 (24.6 %) between 50-64 years, 271 (8.3%) between 65-80 years, 13 (0.4%) over 80 years of age. According to their statements, 2.512 participants (77.6%, 95 % CI 76.2-79 %) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being healthcare workers and individual perceived risk were associated with COVID-19 vaccine acceptance Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty responders (47.6 % 95 % CI 45.9-49.3 %) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial.Conclusions and RelevanceNearly 75 % and 48 % of the survey responders were likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake.

Publisher

Cold Spring Harbor Laboratory

Reference18 articles.

1. Coronavirus disease (COVID-19) Situation Dashboard [Internet]. [accessed 3 apr. 2020]. Available: https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd

2. Ten health issues WHO will tackle this year [Internet]. [accessed 3 apr 2020]. Available: https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019

3. Lurie N , Saville M , Hatchett R , Halton J. Developing Covid-19 Vaccines at Pandemic Speed. New England Journal of Medicine. 30 march 2020;0(0)

4. Le TT, Andreadakis Z , Kumar A , Román RG , Tollefsen S , Saville M ,et al. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery [Internet]. 9 apr 2020 [accessed 12 apr 2020]; Disponible sur: http://www.nature.com/articles/d41573-020-00073-5

5. Eyal N , Lipsitch M , Smith PG . Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis [Internet]. [accessed 3 apr 2020]; Available on: http://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3